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Response to X-radiation and cytotoxic drugs of clonal
subpopulations of different ploidy and metastatic potential
isolated from RIF-1 mouse sarcoma
J.G. Reeve, K.A. Wright & P.R. Twentyman
MRC Clinical Oncology and Radiotherapeutics Unit, MRC Centre, Hills Road, Cambridge CB2 2QH.
Summary Clonal subpopulations of different ploidy values and metastatic capacities, isolated from the
RIF-1 mouse sarcoma, have been tested for in vitro X-radiation sensitivity, for in vitro sensitivity to adriamycin
and for in vitro and in vivo sensitivity to melphalan and CCNU. Following X-radiation, no consistent
differences in the survival curve characteristics (Do and n) of diploid, tetraploid and octoploid cells were
observed. In addition no relationship between radiation response and metastatic capacity was observed. For
drug response, no marked differences were found in the dose response curves of RIF-1 clones treated in vitro
with adriamycin. However, a wide variation in the responses of RIF-I clones to in vitro melphalan treatment
was observed which was independent of both ploidy and metastatic capacity. Although the responses of
RIF-1 clones to in vitro CCNU treatment were similarly independent of metastatic capacity, a clear relation-
ship between CCNU sensitivity and ploidy was observed. Thus, all diploid RIF-l clones were markedly more
sensitive to CCNU treatment than either tetraploid or octoploid RIF-l clones. For both melphalan and
CCNU treatment the relative sensitivities in vitro correlated with in vivo sensitivities as assayed by clonogenic
cell survival.
A major focus of interest in studies of tumour cell
heterogeneity has been the implications of such
heterogeneity for metastatic behaviour and
therapeutic response. Numerous studies have
demonstrated the presence within primary tumours
of cells with differing metastatic ability (for review,
Poste & Fidler, 1980) and with different
susceptibilities to cytotoxic agents (Hakansson &
Trope, 1974a,b; Palyi et al., 1977; Heppner et al.,
1978). Furthermore, differences in drug response
between cells populating metastases and those
isolated from the localized "primary" tumour have
also been reported (Tsuruo & Fidler, 1981).
Many tumour cell populations are also known to
be heterogeneous with respect to chromosome
number and DNA content (Stich, 1960; Spooner &
Cooper, 1972; Nowell, 1976; Suzuki et al., 1977).
Although the relationship between DNA content
and metastasizing ability has been the subject of
several investigations (Suzuki et al., 1978; 1980), few
studies have addressed the relationship between
ploidy and response to cytotoxic drugs. Since many
agents currently used in cancer therapy interact
directly or indirectly with DNA, we have carried
out such a study using the RIF-1 mouse sarcoma.
By means of flow cytometry and chromosome
analysis the RIF-1 tumour has been shown to be
comprised of both diploid and tetraploid
subpopulations of clonogenic tumour cells
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(Twentyman et al., 1980). In the previous paper,
(Reeve & Twentyman, this issue) we described how
clonal variants with differing ploidy levels, including
diploid, tetraploid and octoploid values, were
isolated from the parent RIF-1 tumour by in vitro
cloning. The metastasizing capacities of the
subpopulations of differing ploidy were established
using an experimental metastasis assay. Isolation of
RIF-1 clonal lines of defined ploidy and metastatic
ability allows an evaluation of the influence of these
2 parameters on therapeutic response. In the
present study, we have assessed the in vivo and in
vitro sensitivities of clonal variants of different
ploidy values and of different metastatic abilities to
the drugs Adriamycin, CCNU and Melphalan,
together with their in vitro sensitivity to x-radiation.
Materials and methods
Mice
C3H/Km mice bred in this unit were used in all
experiments. This colony was derived from breeding
pairs imported from the C3H/Km colony Stanford
University, California in which the RIF-1 tumour
arose (Twentyman et al., 1980). Animals were age
and sex matched within each experiment.
Tihmour cell lines
The details of the derivation of the RIF-1 tumour,
the in vitro cloning procedures and the selection of
metastatic variants as defined by the lung colony
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assay are described in the previous paper (Reeve &
Twentyman, 1983). The details of flow cytometry
have been described elsewhere (Reeve &
Twentyman, 1982).
The ploidy levels, lung colony formation
efficiencies and the in vitro doubling times of the
RIF-1 clonal variants used in the present study are
summarized in Table I.
Table I Description of RIF-1 clones
Metastatic Doubling
Clone Ploidy1 potential' 2 time3 (h)
2 Diploid 11.0 0.84;
16 Tetraploid 1.1 0.82; 0.74
19 Tetraploid 67.4 0.74; 0.61
20 Tetraploid 29.1 0.78; 0.87
23 Diploid 12.8 0.59; 0.66
21 Octoploid 9.8 1.34;
28 Diploid 0.35 0.72; 0.94
'Reeve & Twentyman, 1983 (previous paper).
2Mean number lung colonies per set of lungs following
i.v. injection of 105 cells. Values represent the mean of 2
independent experiments. For individual determinations
and s.e. values see Reeve & Twentyman, 1983.
3Calculated from the slope of the growth curve for cells
in the exponential phase ofgrowth.
In vitro radiation sensitivity
RIF-1 clonal variants of different ploidy levels and
metastatic abilities were exposed to single doses of
x-radiation ranging from 1.5-16.5 Gy during log
phase monolayer culture in 25cm2 tissue culture
flasks (Sterilin) containing Eagles Minimal Essential
Medium with Earle's salts supplemented with 10%
newborn calf serum (both Gibco Biocult Ltd.) and
antibiotics. Immediately after irradiation, the cells
were removed from the tissue culture flasks using
trypsin as previously described (Twentyman et al.,
1980), counted and various cell numbers were
plated into replicate petri dishes containing
medium. Colonies were incubated for 13 days, then
fixed and stained with crystal violet. Colonies
containing > 50 cells were counted by means of a
dissecting microscope.
A computer program (Watson, 1978) was used to
derive the survival parameters Do and n according
to a linear transform of the multitarget, single hit
radiation survival curve.
In vitro drug sensitivity
RIF-I clones, growing in log phase monolayer
culture in 25cm2 tissue culture flasks, were exposed
to appropriate concentrations of the drug under
study for 1 h. Adriamycin (Pharmitalia Ltd., Italy)
was dissolved in sterile PBS, CCNU (Lundbeck
Ltd., Luton) in absolute ethanol and melphalan
(Burroughs Wellcome Co., London) in acid ethanol.
All drugs were prepared immediately before use and
added to the 5ml of medium overlying the cells in a
volume of 0.1 ml. As a control for each drug under
study 0.1 ml of the appropriate vehicle alone was
added to similar cultures. Immediately after
treatment the cells were rinsed twice, trypsinized,
counted and plated into replicate petri dishes as
described above. Colonies were incubated for 13
days and counted.
In vivo drug sensitivity
Tumours were established from RIF-1 clones by
inoculating 105 cells into the gastrocnemius muscle
of the hind leg. Tumours were treated when they
had reached - volume of 300-600mm3. Each
mouse was ear tagged, assigned to treatment groups
on a random basis and treated individually,
Immediately before use CCNU was dissolved in
absolute ethanol, diluted 1:20 in 0.5%
carboxymethyl cellulose/Hanks Balanced Salt
Solution (HBSS). Prior to injection melphalan was
dissolved in acidified ethanol, diluted 1: 10 in
propylene glycol-K2HPO4 buffer. Appropriate
concentrations of either CCNU or melphalan were
injected i.p. Control mice received appropriate
volumes of vehicle alone.
Clonogenic cell survival
Tumour bearing mice were killed 24h after
treatment. Two tumours from mice receiving the
same drug treatment were aseptically excised,
pooled, weighed and disaggregated to yield single
cell suspensions as previously described (Reeve &
Twentyman, 1982). Various cell numbers of each
suspension were plated into triplicate petri dishes
and the cell colonies were counted 13 days later.
Cell killing in vivo was expressed as surviving
fraction (SF).
SF=number of colonies formed by 100
cells from treated tumour
number of colonies formed by 100
cells from untreated tumour
Results
X-ray responses of parent RIF-1 cells and clonal
sublines
Figure 1 shows that the x-ray survival curves
typically obtained for the parent RIF-1 tumour and
the clonal sublines of differing ploidy levels areRESPONSE OF RIF-l SUBPOPULATIONS 843
Dose (Gy)
6 9 12 15 18
AL
0
2.01
1.5-
* A
.
:L
0
0 0 1.OF
0.7-
* Z
.
0.5
4 Parent Diploid Tetraploid Octoploid
10
0
IL
*e
Figure 1 Typical X-ray survival curves obtained for
RIF-l parent cell line and clones of different ploidy
values and metastatic capacities. In the examples
shown: (*) RIF-1 parent; (0) clone 23 (diploid;
intermediate LCFE); clone 19 (tetraploid; high
LCFE); (U) clone 21 (octoploid; low LCFE). Each
point represents the mean survival value obtained from
3 replicate cultures in a single experiment.
similar in shape. Figure 2 shows that the x-ray
sensitivities (Do i.e. a measure of the slope) of both
the parent cell line and the RIF-1 clones were
within the range (1.0-2.0Gy) usually observed for
mammalian cells and that there is no consistent
change in Do with increasing ploidy level. Similarly
there is no consistent difference in the n values (i.e.
the zero dose intercept) obtained for RIF-1 clones
of different ploidy levels and the parent line (Figure
3).
In vitro sensitivity ofRIF-J clones to cytoxic drugs
Adriamycin Over the dose range studied (0-
20pgml-1), tumour cell survival in vitro in the
Figure 2 Radiosensitivities (Do) calculated from a
linear transform of the multitarget X-ray survival curve
of RIF-l parent cell line and RIF-I clones of different
ploidy values and metastatic capacities. Each point
represents the Do value obtained from a single
experiment; error bars represent upper and lower 95%
confidence limits. (*) RIF-1 parent; (5) clone 23
(diploid; intermediate LCFE); (A) clone 28 (diploid;
low LCFE); (0) clone 16 (tetraploid; low LCFE); (A)
clone 19 (tetraploid; high LCFE); (Ol) clone 20
(tetraploid; intermediate LCFE); * clone 21
(octoploid; low LCFE).
presence of adriamycin was similar for each of the
clonal lines and was independent of clonal variation
in ploidy level and metastatic ability.
Melphalan The data showing the response of RIF-
1 clones to melphalan treatment in vitro are shown
in Figure 4. A wide range of sensitivities to this
drug over the dose range studied is evident. Thus
clone 20 is considerably more resistant to
melphalan than clone 16 which is most sensitive to
this drug. Clones 28 and 19 show intermediate
sensitivities. The observed differences in sensitivities
of the clonal lines are again independent of ploidy
level and metastatic ability (Table II).
CCNU Figure 5 shows that over the dose range
studied cell survival in vitro in the presence of
CCNU was similar for the tetraploid clones 16, 19
and 20. However, the diploid clone, 28, is
significantly more sensitive to this agent. No
correlation exists between the metastatic abilities of
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Figure 3 Extrapolation numbers (n) calculated from a
linear transform of the multitarget X-ray survival
curve obtained for RIF-1 parent cell line and RIF-I
clones of different ploidy values and metastatic
capacities. Each point represents the n value obtained
from a single experiment; error bars represent upper
and lower 95% confidence limits. (*) RIF-l parent;
(0) clone 23 (diploid; intermediate LCFE); (A) clone
28 (diploid; low LCFE); (0) clone 16 (tetraploid; low
LCFE); (A) clone 19 (tetraploid; high LCFE); (C])
clone 20 (tetraploid; intermediate LCFE); (U) clone 21
(octoploid; low LCFE).
the clones and their in vitro response to CCNU
(Table II).
The data shown in Figure 6 and Table II show
that the in vitro sensitivity to CCNU treatment
exhibited by the diploid clone 28 similarly
characterizes diploid clones 2 and 23. Clone 19 was
Table II Metastatic potential, ploidy and cytotoxic drug
sensitivity of RIF-1 clones
Relative2 Relative3
Metastatic CCNU melphalan
Clone Potential' Ploidy sensitivity sensitivity
16 Low Tetraploid Resistant Sensitive
19 High Tetraploid Resistant Intermediate
20 Intermediate Tetraploid Resistant Resistant
28 Low Diploid Sensitive Intermediate
23 Intermediate Diploid Sensitive
2 Intermediate Diploid Sensitive
'For definition see Table I.
2See Figure 5.
3See Figure 4.
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Figure 4 Cell survival curves of RIF-I clones of
different ploidy values and metastatic capacities
following in vitro treatment with melphalan. Each
point represents the survival value obtained from a
single experiment. (U) clone 20 (tetraploid;
intermediate LCFE); (0) clone 19 (tetraploid; high
LCFE); (0) clone 28 (diploid; low LCFE); (A) clone
16 (tetraploid; low LCFE).
used as a standard throughout these experiments
(Figure 5) to typify the relative resistance of
tetraploid clones to CCNU treatment.
Figure 7 shows that over the dose range studied,
cell survival in vitro in the presence of CCNU was
similar for tetraploid clone 20 and octoploid clone
21. Both are markedly more resistant to CCNU
treatment than diploid clone 28. However,
octoploid clone 21 is no more resistant to in vitro
treatment with CCNU than tetraploid clone 20.
In vivo sensitivity of RIF-I clones to
chemotherapeutic agents
We have examined whether the observed clonal
variation in response to melphalan and CCNU
treatment in vitro was also detectable in vivo.
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(a) Melphalan Pigure 8 shows data for the in vitro
cell survival response of RIF-1 clones treated in
vivo with melphalan. Within the range of doses
studied clone 20 was less sensitive than clones 16,
19 and 28 with clone 16 being the most sensitive to
melphalan.
(b) CCNU Figure 9 shows data for the in vitro
cell survival response of RIF-1 clones treated in
vivo with CCNU. Within the range of doses studied
diploid clone 28 was most sensitive to CCNU
treatment with tetraploid clones 16, 19 and 20
being considerably less sensitive.
Discussion
We have examined the effect of ploidy and
metastatic ability on the responses of RIF-1 clonal
subpopulations to x-radiation and cytotoxic agents.
A number of clinical observations (De, 1961;
Atkin et al., 1959) as well as some in vivo and in
vitro radiobiological studies (Revesz & Norman,
1960; Puck, 1960; Berry, 1963) have suggested a
relationship between ploidy and radiation response.
However, in the present study no relationship
between ploidy and Do values was observed for
ploidy variants of the RIF-1 tumour. Similarly no
relationship was found between the extrapolation
Figure 6 Cell survival curves of tetraploid clone 19
(0), diploid clone 2 (V) and diploid clone 23 (V)
following in vitro treatment with CCNU. Each point
represents the survival value obtained from a single
experiment.
number and ploidy ofcells having diploid, tetraploid
or octoploid values. Our findings are in agreement
with other in vitro studies (Till, 1961; Lockart et al.,
1961; Rommelaire & Errera, 1972; Limbosh et al.,
1974; Millar & Millar, 1977) which indicate that
chromosome number per se does not correlate with
radiation response.
For drug response, no significant differences in
the dose response curves of RIF-1 clones treated
with adriamycin was observed. However, our data
demonstrate wide variation in the responses of
RIF-1 clones to in vitro melphalan and CCNU
treatment. Furthermore, the relative sensitivities in
vitro are correlated with in vivo sensitivities in terms
of clonogenic cell survival assayed in vitro. This
latter finding contrasts with lack of correlation
between in vitro and in vivo drug sensitivities
observed for tumour cell subpopulations derived
from a mammary adenocarcinoma (Heppner et al.,
1978).
The clonal variation in drug sensitivity observed
for melphalan is independent of ploidy. Thus, the846 J.G. REEVE et al.
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Figure 7 Cell survival curves of octoploid clone 21
(l); tetraploid clone 20 (U) and diploid clone 28 (0).
Each point represents the survival value obtained from
a single experiment. Poisson errors on the individual
points are small compared to the inter-experimental
variation. line drawn through data for clone 20
in Figure 5. ---- line drawn through data for clone 28
in Figure 5.
resistance of tetraploid clone 20 to this drug, is not
shared by tetraploid clones 16 and 19. Clone 16
shows greatest sensitivity to melphalan being more
sensitive than diploid clone 28 and tetraploid clone
19. A good correlation, however, exists between
CCNU sensitivity and ploidy. Thus, all 3 diploid
RIF-1 clones were significantly more sensitive to in
vitro CCNU treatment than tetraploid or octoploid
clones.
Whilst a number of studies have demonstrated
the presence of subpopulations of tumour cells with
markedly different drug sensitivities (Hakansson &
Trope, 1974a,b; Palyi et al., 1977; Heppner et al.,
1978; Tsuruo & Fidler, 1981) no-one to our
knowledge, has reported ploidy-dependent drug
responses. No correlation, however, between drug
response and metastatic ability was observed for
the RIF-1 clones examined in the present study.
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Figure 8 Clonogenic cell survival following in vivo
treatment of RIF-1 clones grown as solid tumours in
C3H/Km mice and treated with melphalan. Poisson
errors on the individual points are small compared to
the inter-experimental variation. (U) clone 20
(tetraploid; intermediate LCFE); (0) clone 19
(tetraploid; high LCFE); (0) clone 28 (diploid; low
LCFE); (A) clone 16 (tetraploid; low LCFE); Each
point represents the survival value obtained from a
single experiment.
Our data show that there is no correlation
between the growth kinetics of the clones and their
drug sensitivities. This finding is in agreement with
similar observations (Hakansson & Trope, 1973;
Van Putten, 1974) which also suggest that
differences in clone sensitivity to drug treatment are
not likely to be explained by small differences in
cell proliferation. We are currently examining
CCNU and melphalan transport in cells of RIF-1
subpopulations which differ in their sensitivities to
these agents, together with DNA repair properties,
in an attempt to elucidate the cellular differences
responsible for the diverse responses of RIF- 1
clones to these agents.
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Figure 9 As for Figure 8 except following in vivo
treatment with CCNU.-
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